Medical Devices India

India Rare Disease Genetic Testing Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

India Rare Disease Genetic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Patient, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $28.8 Mn Placeholder estimate
Estimate 2025 $33.1 Mn 1.9% of the global market
Projected 2034 $116.3 Mn 251.8% Adds $83.2 Mn over 9 forecast years
CAGR 2025–2034 15.0% Faster than 76% of 173 Medical Devices markets here
Key players 5 Companies profiled
  • India is 1.88% of the global market.
  • In APAC, the largest is China at $135.1 Mn.
  • Fastest growing: India (this report) at 15% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$83.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Rare Disease Genetic Testing Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $28.8 Mn — —
2025 (base) $33.1 Mn +$4.3 Mn —
2026 (forecast) $38.0 Mn +$5.0 Mn +15%
2027 (forecast) $43.7 Mn +$5.7 Mn +32.3%
2028 (forecast) $50.3 Mn +$6.6 Mn +52.1%
2029 (forecast) $57.8 Mn +$7.5 Mn +74.9%
2030 (forecast) $66.5 Mn +$8.7 Mn +101.1%
2031 (forecast) $76.5 Mn +$10.0 Mn +131.3%
2032 (forecast) $87.9 Mn +$11.5 Mn +166%
2033 (forecast) $101.1 Mn +$13.2 Mn +205.9%
2034 (forecast) $116.3 Mn +$15.2 Mn +251.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

India Rare Disease Genetic Testing Market Analysis at a glance
Market size, 2025$33.1 Mn placeholder estimate
Forecast, 2034$116.3 Mn placeholder estimate
Growth (CAGR), 2025–203415.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, patient and end user (see all)
Key playersGeneDx, Invitae, Blueprint Genetics (Quest), Fulgent Genetics, CENTOGENE (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Rare Disease Genetic Testing Market Analysis Executive Summary

Rare disease genetic testing uses exome and genome sequencing to find the genetic cause of rare conditions, often in children.

Key segments of the rare Disease Genetic Testing market include test (Whole Exome Sequencing, Whole Genome Sequencing and Gene Panels) and patient (Pediatric, Adult and Prenatal).

Bar chart: India Rare Disease Genetic Testing market size, 2024–2034, placeholder estimates. $28.8 Mn in 2024, $33.1 Mn in 2025 and $116.3 Mn in 2034, 15.0% CAGR.
India Rare Disease Genetic Testing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Rare Disease Genetic Testing Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the rare Disease Genetic Testing market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the rare Disease Genetic Testing market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the rare Disease Genetic Testing market.

Competitive Landscape for Rare Disease Genetic Testing Market in India

The rare Disease Genetic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Rare Disease Genetic Testing Market in India

Rare Disease Genetic Testing in India: rules and payment

Since October 2023, every medical device sold in India needs a licence under the Medical Devices Rules, 2017, from the Central Drugs Standard Control Organisation (CDSCO) or, for some lower-risk devices made in India, a state authority.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how rare Disease Genetic Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Rare Disease Genetic Testing right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Rare Disease Genetic Testing in context

India compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 10th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 11th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 7.4% of people (2025). World: 10.4% of people (2025). 11th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Rare Disease Genetic Testing market in India?
Placeholder estimate: about $33.1 Mn in 2025, rising to about $116.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Rare Disease Genetic Testing market in India growing?
Placeholder estimate: about 15.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Rare Disease Genetic Testing market report cover?
The report splits the market by test (Whole Exome Sequencing, Whole Genome Sequencing, Gene Panels), patient (Pediatric, Adult, Prenatal) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Rare Disease Genetic Testing market?
Key players include GeneDx, Invitae, Blueprint Genetics (Quest), Fulgent Genetics and CENTOGENE.
What is driving the Rare Disease Genetic Testing market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the rare Disease Genetic Testing market.
Who regulates Rare Disease Genetic Testing in India?
Since October 2023, every medical device sold in India needs a licence under the Medical Devices Rules, 2017, from the Central Drugs Standard Control Organisation (CDSCO) or, for some lower-risk devices made in India, a state authority. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
How much research is published on Rare Disease Genetic Testing?
PubMed lists 899 papers on Rare Disease Genetic Testing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in India

See all

Related on rare diseases and genomics

See the topic